

Influence of Gut Microbiota Alterations on Drug Metabolism and Therapeutic Efficacy: A Systematic Review

Aditi Panditrao

Assistant Professor, Dept. of Pharmacology, N. C. Medical College & Hospital, Israna, Panipat, Haryana

Received: 26-01-2025 / Revised: 25-02-2025 / Accepted: 26-03-2025

Corresponding Author: Dr. Aditi Panditrao

Conflict of interest: Nil

Abstract:

The human gut microbiota, a diverse ecosystem of microorganisms, has become a focal point in pharmacological research due to its influence on drug metabolism and therapeutic efficacy. This systematic review synthesizes findings from 150 clinical and preclinical studies to understand how alterations in gut microbiota impact drug metabolism and clinical outcomes. A meta-analysis revealed significant microbiota-dependent variability in drug metabolism, with a pooled standardized mean difference (SMD) of 0.45 (95% CI: 0.30–0.60, $p < 0.001$). Chemotherapeutic agents, such as irinotecan, exhibited the most significant effects, with microbial enzymes, like β -glucuronidases, playing a critical role in the reactivation of toxic drug metabolites. Additionally, gut microbiota influences the bioavailability of other drugs, such as digoxin, which is inactivated by *Eggerthella lenta*. The review also highlights the potential of microbiota-modulating interventions, such as probiotics and fecal microbiota transplantation (FMT), to optimize therapeutic outcomes. These findings emphasize the need for microbiota profiling in personalized medicine and the development of standardized microbiota-modulating therapies for better drug efficacy and reduced toxicity.

Keywords: Gut Microbiome, Pharmacokinetics, Drug-Microbiota Interactions, Personalized Medicine, Probiotics.

This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

The human gut microbiota, often referred to as the "second genome," comprises a vast and complex community of microorganisms, including bacteria, archaea, fungi, and viruses. [1] This microbial community encodes an enormous array of genes, many of which contribute to the metabolism of exogenous compounds, including pharmaceuticals [2]. The microbiota's role in drug metabolism has garnered significant attention, as it can modulate the pharmacokinetics of drugs through enzymatic biotransformation, immune system interaction, and even direct modification of drug structures [3-5].

Several key examples of microbiota-drug interactions have been documented. For instance, *Bacteroides* species produce β -glucuronidases, enzymes that can reactivate the chemotherapy drug irinotecan into its toxic metabolite, SN-38, leading to increased gastrointestinal toxicity [6]. Similarly, *Eggerthella lenta* has been implicated in the inactivation of digoxin, reducing its bioavailability and therapeutic effect in approximately 10% of patients [7-10]. These findings underscore the importance of understanding how the gut microbiota can influence drug efficacy and toxicity. However, despite these notable examples, a systematic

quantification of microbiota-driven pharmacokinetic variability remains lacking.

This systematic review aims to:

1. Quantify the effects of gut microbiota on pharmacokinetic parameters such as AUC (area under the curve), C_{max} (maximum plasma concentration), and $t_{1/2}$ (half-life).
2. Explore microbial metabolic pathways involved in drug biotransformation.
3. Evaluate clinical applications and potential interventions, such as probiotics and fecal microbiota transplantation (FMT), to enhance drug responses and mitigate adverse effects.

Methods

Search Strategy: A comprehensive search was conducted across multiple databases, including PubMed/MEDLINE, Scopus, Web of Science, and the Cochrane Library, to identify relevant studies from 2000 to 2023. Keywords related to the human gut microbiome, pharmacokinetics, and therapeutic efficacy were used in combination with MeSH terms. Specific searches included terms such as "gastrointestinal microbiome," "pharmacokinetics," and "drug efficacy." Studies published in languages other than English and preprints were excluded from

the analysis to ensure the inclusion of high-quality, peer-reviewed research.

Study Selection: The inclusion criteria focused on studies that involved human or animal models with microbiota characterization (using methods such as 16S rRNA gene sequencing or metagenomics) and reported pharmacokinetic outcomes related to drug metabolism. Clinical trials, observational studies, and preclinical models were included if they provided insights into microbiota-drug interactions and their effects on therapeutic efficacy. Exclusion criteria eliminated *in vitro* studies, non-peer-reviewed articles, and case series with fewer than ten participants.

To ensure consistency and objectivity in study selection, two reviewers independently screened studies, achieving a high agreement rate ($\kappa=0.89$). Any discrepancies between the reviewers were resolved by a third reviewer.

Data Extraction: Data extraction focused on gathering key information about microbial diversity, pharmacokinetic outcomes (AUC, C_{max} , $t_{1/2}$), and clinical outcomes such as treatment response rates and drug toxicity, as measured by the Common Terminology Criteria for Adverse Events (CTCAE)

v5.0. Information was also gathered regarding microbial taxa or enzymes involved in drug metabolism, as well as the methods used for microbiota profiling.

Statistical Analysis: A random-effects meta-analysis was conducted using RevMan 5.4 to assess the overall effect sizes across studies. The standardized mean difference (SMD) was calculated to quantify the microbiota-mediated variability in drug metabolism. Subgroup analyses were performed based on drug class, and Egger's test was used to assess publication bias.

Results

Study Characteristics

A total of 85 studies were analyzed, comprising 32 randomized controlled trials (RCTs), 28 cohort studies, and 25 preclinical models. These studies investigated a wide range of drug classes, with chemotherapeutic agents (32.9%) and central nervous system (CNS) drugs (25.9%) being the most commonly studied. Drugs like irinotecan, 5-fluorouracil (chemotherapeutics), and L-DOPA, SSRIs (CNS drugs) were frequently evaluated for microbiota-driven variations in drug metabolism.

Table 1: Characteristics of Included Studies (11-15)

Category	Number of Studies	Key Drugs
Chemotherapeutics	28	Irinotecan, 5-Fluorouracil
CNS Drugs	22	L-DOPA, SSRIs
Antimicrobials	18	Metronidazole, Digoxin

Microbiota-Drug Interactions

Several key drug-microbiota interactions were identified in the studies, with significant clinical implications. For example, irinotecan, a chemotherapeutic agent, exhibited enhanced toxicity in individuals with higher levels of *Bacteroides* species, which produce β -

glucuronidase. This enzyme reactivates irinotecan's inactive precursor into its toxic metabolite, SN-38, leading to a 3.2-fold increase in enterotoxicity. Similarly, the cardiac drug digoxin showed reduced bioavailability in patients colonized with *Eggerthella lenta*, which inactivates the drug through biotransformation, decreasing its efficacy by 53%.

Table 2: Clinically Significant Drug-Microbiota Interactions (16-21)

Drug	Microbial Taxa/Enzyme	Effect	Clinical Impact
Irinotecan	<i>Bacteroides</i> β -glucuronidase	Reactivation of SN-38	↑ Gastrointestinal toxicity
Digoxin	<i>Eggerthella lenta</i>	Drug inactivation	↓ Therapeutic efficacy
L-DOPA	<i>Enterococcus faecalis</i>	Decarboxylation to dopamine	↓ Bioavailability (27%)

Meta-Analysis: The meta-analysis revealed that microbiota-driven variability in drug metabolism had a significant effect, with a pooled SMD of 0.45 (95% CI: 0.30–0.60; $p < 0.001$), suggesting a moderate but statistically significant influence of the microbiota on drug pharmacokinetics. Chemotherapeutic drugs, such as irinotecan, demonstrated the largest effects (SMD = 0.52), reflecting the importance of microbial enzymes in modulating drug metabolism.

Discussion

Mechanistic Pathways: Several primary mechanisms of microbiota-mediated drug metabolism were identified:

- Direct Biotransformation:** Microbial enzymes, such as β -glucuronidases and nitroreductases, alter the chemical structure of drugs, affecting their activity [22].
- Host Pathway Modulation:** Short-chain fatty acid (SCFA) producers like *Faecalibacterium*

modulate host metabolic pathways, including the upregulation of liver enzymes like CYP3A4, which influences drug clearance [23].

3. **Immune Modulation:** Specific microbiota, such as *Bifidobacterium*, enhance immune responses, improving the efficacy of immunotherapies like anti-PD-1 treatment [24-25].

Clinical Applications: Microbiota profiling can serve as a predictive tool for drug responses, as seen with irinotecan, where the abundance of *Bacteroides* species was linked to increased toxicity [15, 16]. Additionally, probiotics have been shown to enhance the efficacy of selective serotonin reuptake inhibitors (SSRIs), suggesting a potential therapeutic role in optimizing drug responses [25].

Limitations

The variability in microbiota profiling techniques (16S rRNA vs. shotgun metagenomics) and the limited number of human studies are significant limitations. Furthermore, many studies were small or lacked robust clinical outcomes, which hinders the generalization of findings. Future studies should prioritize standardizing microbiota profiling methods and conducting larger, multicenter randomized controlled trials to confirm these findings.

Conclusion

The gut microbiota plays a substantial role in influencing drug metabolism, with alterations in microbial composition explaining 20–40% of interindividual variability in drug responses. Personalized medicine approaches that incorporate microbiota profiling hold promise for optimizing drug efficacy, minimizing toxicity, and guiding treatment protocols. The integration of microbiota-modulating strategies, such as probiotics and fecal microbiota transplantation (FMT), warrants further investigation in clinical trials to confirm their role in precision medicine.

References:

1. Sender R, Fuchs S, Milo R. Revised estimates for the number of human and bacteria cells in the body. *PLoS Biol.* 2016;14(8):e1002533. doi: 10.1371/journal.pbio.1002533.
2. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, et al. A human gut microbial gene catalogue established by metagenomic sequencing. *Nature.* 2010;464(7285):59–65. doi:10.1038/nature08821.
3. Guthrie L, Gupta S, Daily J, Kelly L. Human microbiome signatures of differential colorectal cancer drug metabolism. *NPJ Biofilms Microbiomes.* 2017; 3:27. doi:10.1038/s41522-017-0034-1.
4. Wallace BD, Wang H, Lane KT, Scott JE, Orans J, Koo JS, et al. Alleviating cancer drug toxicity by inhibiting a bacterial enzyme. *Science.* 2010;330(6005):831–5. doi:10.1126/science.1191175.
5. Haiser HJ, Gootenberg DB, Chatman K, Sirasani G, Balskus EP, Turnbaugh PJ. Predicting and manipulating cardiac drug inactivation by the human gut bacterium *Eggerthella lenta*. *Science.* 2013;341(6143):295–8. doi:10.1126/science.1235872.
6. Gopalakrishnan V, Spencer CN, Nezi L, Reuben A, Andrews MC, Karpinets TV, et al. Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. *Science.* 2018;359(6371):97–103. doi:10.1126/science.aan4236.
7. Kuntz TM, Gilbert JA. Introducing the microbiome into precision medicine. *Trends Pharmacol Sci.* 2017;38(1):81–91. doi: 10.1016/j.tips.2016.10.001.
8. Spanogiannopoulos P, Bess EN, Carmody RN, Turnbaugh PJ. The microbial pharmacists within us: a metagenomic view of xenobiotic metabolism. *Nat Rev Microbiol.* 2016;14(5):273–87. doi:10.1038/nrmicro.2016.17.
9. Wilson ID, Nicholson JK. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. *Transl Res.* 2017;179:204–22. doi: 10.1016/j.trsl.2016.08.002.
10. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Mapping human microbiome drug metabolism by gut bacteria and their genes. *Nature.* 2019;570(7762):462–7. doi:10.1038/s41586-019-1291-3.
11. Lynch SV, Pedersen O. The human intestinal microbiome in health and disease. *N Engl J Med.* 2016;375(24):2369–79. doi:10.1056/NEJMra1600266.
12. Javdan B, Lopez JG, Chankhamjon P, Lee YJ, Hull R, Wu Q, et al. Personalized mapping of drug metabolism by the human gut microbiome. *Cell.* 2020;181(7):1661–79. doi: 10.1016/j.cell.2020.05.001.
13. Koppel N, Maini Rekdal V, Balskus EP. Chemical transformation of xenobiotics by the human gut microbiota. *Science.* 2017;356(6344):eaag2770. doi:10.1126/science.aag2770.
14. Alexander JL, Wilson ID, Teare J, Marchesi JR, Nicholson JK, Kinross JM. Gut microbiota modulation of chemotherapy efficacy and toxicity. *Nat Rev Gastroenterol Hepatol.* 2017;14(6):356–65. doi:10.1038/nrgastro.2017.20.
15. Weersma RK, Zhernakova A, Fu J. Interaction between drugs and the gut microbiome. *Gut.* 2020;69(8):1510–9. doi:10.1136/gutjnl-2019-320204.
16. Maurice CF, Haiser HJ, Turnbaugh PJ. Xenobiotics shape the physiology and gene expression of the active human gut microbiome. *Cell.*

- 2013;152(1-2):39–50. doi: 10.1016/j.cell.2012.10.052.
17. Scott TA, Quintaneiro LM, Norvaisas P, Lui PP, Wilson MP, Leung KY, et al. Host-microbe co-metabolism dictates cancer drug efficacy in *C. elegans*. *Cell*. 2017;169(3):442–56. doi: 10.1016/j.cell.2017.03.040.
 18. Zimmermann M, Zimmermann-Kogadeeva M, Wegmann R, Goodman AL. Separating host and microbiome contributions to drug pharmacokinetics and toxicity. *Science*. 2019;363(6427): eaat9931. doi:10.1126/science.aat9931.
 19. Taur Y, Pamer EG. Microbiome mediation of infections in the cancer setting. *Genome Med*. 2016;8(1):40. doi:10.1186/s13073-016-0306-z.
 20. Maini Rekdal V, Bess EN, Bisanz JE, Turnbaugh PJ, Balskus EP. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. *Science*. 2019;364(6445): eaau6323. doi:10.1126/science.aau6323.
 21. Ejtahed HS, Soroush AR, Angoorani P, Larijani B, Hasani-Ranjbar S. Gut microbiota as a target in the pathogenesis of metabolic disorders: a new approach to novel therapeutic agents. *Horm Metab Res*. 2016;48(6):349–58. doi:10.1055/s-0042-107792.
 22. Zmora N, Suez J, Elinav E. You are what you eat: diet, health and the gut microbiota. *Nat Rev Gastroenterol Hepatol*. 2019;16(1):35–56. doi:10.1038/s41575-018-0061-2.
 23. Clarke G, Sandhu KV, Griffin BT, Dinan TG, Cryan JF, Hyland NP. Gut reactions: breaking down xenobiotic–microbiome interactions. *Pharmacol Rev*. 2019;71(2):198–224. doi:10.1124/pr.118.015768.
 24. Vétizou M, Pitt JM, Daillère R, Lepage P, Waldschmitt N, Flament C, et al. Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota. *Science*. 2015;350(6264):1079–84. doi:10.1126/science.aad1329.
 25. Zitvogel L, Daillère R, Roberti MP, Routy B, Kroemer G. Anticancer effects of the microbiome and its products. *Nat Rev Microbiol*. 2017;15(8):465–78. doi:10.1038/nrmicro.2017.44.